Details

Autor(en) / Beteiligte

• Martinez‐Martin, Pablo
• Reddy, Prashanth
• Katzenschlager, Regina
• Antonini, Angelo
• Todorova, Antoniya
• Odin, Per
• Henriksen, Tove
• Martin, Anne
• Calandrella, Daniela
• Rizos, Alexandra
• Bryndum, Narissah
• Glad, Arne
• Dafsari, Haidar Salimi
• Timmermann, Lars
• Ebersbach, Georg
• Kramberger, Milica G.
• Samuel, Michael
• Wenzel, Karoline
• Tomantschger, Volker
• Storch, Alexander
• Reichmann, Heinz
• Pirtosek, Zvezdan
• Trost, Maja
• Svenningsson, Per
• Palhagen, Sven
• Volkmann, Jens
• Chaudhuri, K. Ray

Titel

Euro I nf: A M ulticenter C omparative O bservational S tudy of A pomorphine and L evodopa I nfusion in P arkinson's D isease

Ist Teil von

• Movement disorders, 2015-04, Vol.30 (4), p.510-516

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• ABSTRACT Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa infusion (IJLI) are two treatment options for patients with advanced Parkinson's disease (PD) and refractory motor complications, with varying cost of treatment. There are no multicenter studies comparing the effects of the two strategies. This open‐label, prospective, observational, 6‐month, multicenter study compared 43 patients on Apo (48.8% males, age 62.3 ± 10.6 years; disease duration: 14 ± 4.4 years; median H & Y stage 3; interquartile range [IQR]: 3‐4) and 44 on IJLI (56.8% males, age 62.7 ± 9.1 years; disease duration: 16.1 ± 6.7 years; median H & Y stage 4; IQR, 3‐4). Cohen's effect sizes (≥0.8 considered as large) were “large” with both therapies with respect to total motor, nonmotor, and quality‐of‐life scores. The Non‐Motor Symptoms Scale (NMSS) with Apo showed moderate improvement, whereas sleep/fatigue, gastrointestinal, urinary, and sexual dimensions of the NMSS showed significantly higher improvement with IJLI. Seventy‐five percent on IJLI improved in their quality‐of‐life and nonmotor symptoms (NMS), whereas in the Apo group, a similar proportion improved in quality of life, but 40% in NMS. Adverse effects included peritonitis with IJLI and skin nodules on Apo. Based on this open‐label, nonrandomized, comparative study, we report that, in advanced Parkinson's patients, both IJLI and Apo infusion therapy appear to provide a robust improvement in motor symptoms, motor complications, quality‐of‐life, and some NMS. Controlled, randomized studies are required. © 2014 International Parkinson and Movement Disorder Society